Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel

John M Fitzpatrick; Joaquim Bellmunt; Karim Fizazi; Axel Heidenreich; Cora N Sternberg; Bertrand Tombal; Antonio Alcaraz; Amit Bahl; Sergio Bracarda; Giuseppe Di Lorenzo; Eleni Efstathiou; Stephen P Finn; Sophie Fosså; Silke Gillessen; Pirkko-Liisa Kellokumpu-Lehtinen; Frédéric E Lecouvet; Stephane Oudard; Theo M de Reijke; Craig N Robson; Maria De Santis; Bostjan Seruga; Ronald de Wit

doi:10.1016/j.ejca.2014.03.010

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel

John M Fitzpatrick
, Joaquim Bellmunt
, Karim Fizazi
, Axel Heidenreich
, Cora N Sternberg
, Bertrand Tombal
, Antonio Alcaraz
, Amit Bahl
, Sergio Bracarda
, Giuseppe Di Lorenzo
, Eleni Efstathiou
, Stephen P Finn
, Sophie Fosså
, Silke Gillessen
, Pirkko-Liisa Kellokumpu-Lehtinen
, Frédéric E Lecouvet
, Stephane Oudard
, Theo M de Reijke
, Craig N Robson
, Maria De Santis

Bostjan Seruga, Ronald de Wit

University Hospital del Mar
University Hospital Aachen
San Camillo Forlanini Hospital
Hospital Clinic Barcelona
University Hospitals Bristol NHS Foundation Trust
Istituto Toscano Tumori (ITT)
Universita di Napoli (University of Naples Federico II)
University of Texas MD Anderson Cancer Center
Oslo University Hospital
Kantonsspital St Gallen
Tampere University Hospital
Georges Pompidou European Hospital
Academic Medical Center
Newcastle University
Ludwig Boltzmann Institute for Applied Cancer Research
Institute of Oncology Ljubljana
Erasmus MC
Irish Cancer Society
University College Dublin
Institut de Cancerlogie Gustave Roussy
University of Paris Sud
Cliniques Universitaires Saint-Luc
St James's Hospital
University of Dublin Trinity College

Research output: Contribution to journal › Article › peer-review

Abstract

The exponential growth of novel therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the last decade has created an acute need for education and guidance of clinicians regarding optimal strategies for patient management. A multidisciplinary panel of 21 European experts in mCRPC assembled for comprehensive discussion and consensus development, seeking to move the field forward and provide guidance and perspectives on optimal selection and sequencing of therapeutic agents and monitoring of response to treatment and disease progression. A total of 110 clinically-relevant questions were addressed and a modified Delphi method was utilised to obtain a consensus. The panel reached a consensus on several important issues, providing recommendations on appropriate phase III clinical trial end-points and optimal strategies for imaging and monitoring of bone metastases. Guidance regarding selection and sequencing of therapy in patients with newly diagnosed or progressive mCRPC is emphasised, including the use of novel bone-targeted agents, chemotherapy, androgen receptor pathway-targeted agents and immunotherapy. The impact of drug resistance and prostate-specific antigen flare on treatment decisions was also addressed. Ultimately, individualised therapy for patients with mCRPC is dependent on continued refinement of clinical decision-making based on patient and disease characteristics. This consensus statement offers clinicians expert guidance on the implementation of recent advances to improve patient outcome, focusing on the future of prostate cancer care.

Original language	English
Pages (from-to)	1617-1627
Number of pages	11
Journal	European journal of cancer (Oxford, England : 1990)
Volume	50
Issue number	9
DOIs	https://doi.org/10.1016/j.ejca.2014.03.010
Publication status	Published - Jun 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Androgen Receptor Antagonists/therapeutic use
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Bone Density Conservation Agents/therapeutic use
Clinical Trials as Topic
Combined Modality Therapy/methods
Diagnostic Imaging/methods
Disease Progression
Drug Resistance, Neoplasm
Humans
Immunotherapy/methods
Male
Prostatic Neoplasms, Castration-Resistant/diagnosis
Treatment Outcome

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

Access to Document

10.1016/j.ejca.2014.03.010

Cite this

Fitzpatrick, J. M., Bellmunt, J., Fizazi, K., Heidenreich, A., Sternberg, C. N., Tombal, B., Alcaraz, A., Bahl, A., Bracarda, S., Di Lorenzo, G., Efstathiou, E., Finn, S. P., Fosså, S., Gillessen, S., Kellokumpu-Lehtinen, P.-L., Lecouvet, F. E., Oudard, S., de Reijke, T. M., Robson, C. N., ... de Wit, R. (2014). Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. European journal of cancer (Oxford, England : 1990), 50(9), 1617-1627. https://doi.org/10.1016/j.ejca.2014.03.010

@article{62d6cae8736d47a79c8c90f8ae77da1a,

title = "Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel",

abstract = "The exponential growth of novel therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the last decade has created an acute need for education and guidance of clinicians regarding optimal strategies for patient management. A multidisciplinary panel of 21 European experts in mCRPC assembled for comprehensive discussion and consensus development, seeking to move the field forward and provide guidance and perspectives on optimal selection and sequencing of therapeutic agents and monitoring of response to treatment and disease progression. A total of 110 clinically-relevant questions were addressed and a modified Delphi method was utilised to obtain a consensus. The panel reached a consensus on several important issues, providing recommendations on appropriate phase III clinical trial end-points and optimal strategies for imaging and monitoring of bone metastases. Guidance regarding selection and sequencing of therapy in patients with newly diagnosed or progressive mCRPC is emphasised, including the use of novel bone-targeted agents, chemotherapy, androgen receptor pathway-targeted agents and immunotherapy. The impact of drug resistance and prostate-specific antigen flare on treatment decisions was also addressed. Ultimately, individualised therapy for patients with mCRPC is dependent on continued refinement of clinical decision-making based on patient and disease characteristics. This consensus statement offers clinicians expert guidance on the implementation of recent advances to improve patient outcome, focusing on the future of prostate cancer care. ",

keywords = "Androgen Receptor Antagonists/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Bone Density Conservation Agents/therapeutic use, Clinical Trials as Topic, Combined Modality Therapy/methods, Diagnostic Imaging/methods, Disease Progression, Drug Resistance, Neoplasm, Humans, Immunotherapy/methods, Male, Prostatic Neoplasms, Castration-Resistant/diagnosis, Treatment Outcome",

author = "Fitzpatrick, \{John M\} and Joaquim Bellmunt and Karim Fizazi and Axel Heidenreich and Sternberg, \{Cora N\} and Bertrand Tombal and Antonio Alcaraz and Amit Bahl and Sergio Bracarda and \{Di Lorenzo\}, Giuseppe and Eleni Efstathiou and Finn, \{Stephen P\} and Sophie Foss{\aa} and Silke Gillessen and Pirkko-Liisa Kellokumpu-Lehtinen and Lecouvet, \{Fr{\'e}d{\'e}ric E\} and Stephane Oudard and \{de Reijke\}, \{Theo M\} and Robson, \{Craig N\} and \{De Santis\}, Maria and Bostjan Seruga and \{de Wit\}, Ronald",

year = "2014",

month = jun,

doi = "10.1016/j.ejca.2014.03.010",

language = "English",

volume = "50",

pages = "1617--1627",

journal = "European journal of cancer (Oxford, England : 1990)",

issn = "0959-8049",

publisher = "Elsevier BV",

number = "9",

}

Fitzpatrick, JM, Bellmunt, J, Fizazi, K, Heidenreich, A, Sternberg, CN, Tombal, B, Alcaraz, A, Bahl, A, Bracarda, S, Di Lorenzo, G, Efstathiou, E, Finn, SP, Fosså, S, Gillessen, S, Kellokumpu-Lehtinen, P-L, Lecouvet, FE, Oudard, S, de Reijke, TM, Robson, CN, De Santis, M, Seruga, B & de Wit, R 2014, 'Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel', European journal of cancer (Oxford, England : 1990), vol. 50, no. 9, pp. 1617-1627. https://doi.org/10.1016/j.ejca.2014.03.010

TY - JOUR

T1 - Optimal management of metastatic castration-resistant prostate cancer

T2 - highlights from a European Expert Consensus Panel

AU - Fitzpatrick, John M

AU - Bellmunt, Joaquim

AU - Fizazi, Karim

AU - Heidenreich, Axel

AU - Sternberg, Cora N

AU - Tombal, Bertrand

AU - Alcaraz, Antonio

AU - Bahl, Amit

AU - Bracarda, Sergio

AU - Di Lorenzo, Giuseppe

AU - Efstathiou, Eleni

AU - Finn, Stephen P

AU - Fosså, Sophie

AU - Gillessen, Silke

AU - Kellokumpu-Lehtinen, Pirkko-Liisa

AU - Lecouvet, Frédéric E

AU - Oudard, Stephane

AU - de Reijke, Theo M

AU - Robson, Craig N

AU - De Santis, Maria

AU - Seruga, Bostjan

AU - de Wit, Ronald

PY - 2014/6

Y1 - 2014/6

N2 - The exponential growth of novel therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the last decade has created an acute need for education and guidance of clinicians regarding optimal strategies for patient management. A multidisciplinary panel of 21 European experts in mCRPC assembled for comprehensive discussion and consensus development, seeking to move the field forward and provide guidance and perspectives on optimal selection and sequencing of therapeutic agents and monitoring of response to treatment and disease progression. A total of 110 clinically-relevant questions were addressed and a modified Delphi method was utilised to obtain a consensus. The panel reached a consensus on several important issues, providing recommendations on appropriate phase III clinical trial end-points and optimal strategies for imaging and monitoring of bone metastases. Guidance regarding selection and sequencing of therapy in patients with newly diagnosed or progressive mCRPC is emphasised, including the use of novel bone-targeted agents, chemotherapy, androgen receptor pathway-targeted agents and immunotherapy. The impact of drug resistance and prostate-specific antigen flare on treatment decisions was also addressed. Ultimately, individualised therapy for patients with mCRPC is dependent on continued refinement of clinical decision-making based on patient and disease characteristics. This consensus statement offers clinicians expert guidance on the implementation of recent advances to improve patient outcome, focusing on the future of prostate cancer care.

AB - The exponential growth of novel therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the last decade has created an acute need for education and guidance of clinicians regarding optimal strategies for patient management. A multidisciplinary panel of 21 European experts in mCRPC assembled for comprehensive discussion and consensus development, seeking to move the field forward and provide guidance and perspectives on optimal selection and sequencing of therapeutic agents and monitoring of response to treatment and disease progression. A total of 110 clinically-relevant questions were addressed and a modified Delphi method was utilised to obtain a consensus. The panel reached a consensus on several important issues, providing recommendations on appropriate phase III clinical trial end-points and optimal strategies for imaging and monitoring of bone metastases. Guidance regarding selection and sequencing of therapy in patients with newly diagnosed or progressive mCRPC is emphasised, including the use of novel bone-targeted agents, chemotherapy, androgen receptor pathway-targeted agents and immunotherapy. The impact of drug resistance and prostate-specific antigen flare on treatment decisions was also addressed. Ultimately, individualised therapy for patients with mCRPC is dependent on continued refinement of clinical decision-making based on patient and disease characteristics. This consensus statement offers clinicians expert guidance on the implementation of recent advances to improve patient outcome, focusing on the future of prostate cancer care.

KW - Androgen Receptor Antagonists/therapeutic use

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Bone Density Conservation Agents/therapeutic use

KW - Clinical Trials as Topic

KW - Combined Modality Therapy/methods

KW - Diagnostic Imaging/methods

KW - Disease Progression

KW - Drug Resistance, Neoplasm

KW - Humans

KW - Immunotherapy/methods

KW - Male

KW - Prostatic Neoplasms, Castration-Resistant/diagnosis

KW - Treatment Outcome

U2 - 10.1016/j.ejca.2014.03.010

DO - 10.1016/j.ejca.2014.03.010

M3 - Article

C2 - 24703899

SN - 0959-8049

VL - 50

SP - 1617

EP - 1627

JO - European journal of cancer (Oxford, England : 1990)

JF - European journal of cancer (Oxford, England : 1990)

IS - 9

ER -

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel

Abstract

UN SDGs

Keywords

Research Beacons, Institutes and Platforms

Access to Document

Fingerprint

Cite this